title: Novel kinin B1 receptor agonists with improved pharmacological profiles.
abstract: There is some evidence to suggest that inducible kinin B1 receptors (B1R) may play beneficial and protecting roles in cardiovascular-related pathologies such as hypertension, diabetes, and ischemic organ diseases. Peptide B1R agonists bearing optimized pharmacological features (high potency, selectivity and stability toward proteolysis) hold promise as valuable therapeutic agents in the treatment of these diseases. In the present study, we used solid-phase methodology to synthesize a series of novel peptide analogues based on the sequence of Sar[dPhe(8)]desArg(9)-bradykinin, a relatively stable peptide agonist with moderate affinity for the human B1R. We evaluated the pharmacological properties of these peptides using (1) in vitro competitive binding experiments on recombinant human B1R and B2R (for index of selectivity determination) in transiently transfected human embryonic kidney 293 cells (HEK-293T cells), (2) ex vivo vasomotor assays on isolated human umbilical veins expressing endogenous human B1R, and (3) in vivo blood pressure tests using anesthetized lipopolysaccharide-immunostimulated rabbits. Key chemical modifications at the N-terminus, the positions 3 and 5 on Sar[dPhe(8)]desArg(9)-bradykinin led to potent analogues. For example, peptides 18 (SarLys[Hyp(3),Cha(5), dPhe(8)]desArg(9)-bradykinin) and 20 (SarLys[Hyp(3),Igl(5), dPhe(8)]desArg(9)-bradykinin) outperformed the parental molecule in terms of affinity, functional potency and duration of action in vitro and in vivo. These selective agonists should be valuable in future animal and human studies to investigate the potential benefits of B1R activation.
authors.affiliation: Department of Pharmacology, Université de Sherbrooke, Québec, Canada.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Côté
authors.forename: Martin
authors.initials: M
authors.lastname: Savard
authors.forename: Veronica
authors.initials: V
authors.lastname: Bovenzi
authors.forename: Simon
authors.initials: S
authors.lastname: Bélanger
authors.forename: Josée
authors.initials: J
authors.lastname: Morin
authors.forename: Witold
authors.initials: W
authors.lastname: Neugebauer
authors.forename: Annie
authors.initials: A
authors.lastname: Larouche
authors.forename: Céléna
authors.initials: C
authors.lastname: Dubuc
authors.forename: Fernand
authors.initials: F
authors.lastname: Gobeil
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects; D002460:Cell Line; D006801:Humans; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011487:Protein Conformation; D011817:Rabbits; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D018002:Receptors, Bradykinin / Q000819:agonists*
chemical_list: D008070:Lipopolysaccharides; D010455:Peptides; D018002:Receptors, Bradykinin